174482-81-6

Basic information

• Product Name: Benzoic acid, 4-(1-methylethyl)-3-nitro- (9CI)
• Synonyms: Benzoic acid, 4-(1-methylethyl)-3-nitro- (9CI);4-isopropyl-3-nitrobenzoic acid
• CAS NO: 174482-81-6
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.19864
• Product Categories: AMINOACID
• Mol File: 174482-81-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 4-(1-methylethyl)-3-nitro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(1-methylethyl)-3-nitro- (9CI)(174482-81-6)
• EPA Substance Registry System: Benzoic acid, 4-(1-methylethyl)-3-nitro- (9CI)(174482-81-6)

Safety Data

• Hazardous Substances Data: 174482-81-6(Hazardous Substances Data)

Upstream product

• 130766-92-6 4-isopropyl-3-nitro-benzyl alcohol 
• 7694-45-3 4-(prop-1-en-2-yl)cyclohex-1-ene-1-carboxylic acid 
• 7697-37-2 nitric acid 
• 1634-63-5 1-(4-isopropyl-3-nitrophenyl)ethan-1-one 
• 536-66-3 p-isopropylbenzoic acid 

Downstream Products

• 1581701-00-9 C₂₃H₂₇F₃N₄O₃ 
• 1581701-38-3 N-(2-isopropyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide 
• 1581701-07-6 C₂₃H₂₉F₃N₄O 
• 859174-95-1 3-amino-4-isopropylbenzoic acid 
• 83-34-1 3-Methylindole 
• 99856-00-5 4-isopropyl-3-nitro-benzoic acid methyl ester 

Relevant articles and documents

Substituted benzamides with activity towards EP4 receptors

The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP4 receptor as well as to pharmaceutical compositions comprising them.

Benzene derivatives and pharmaceutical composition

A benzene derivative of the formula (I): STR1 wherein R 1 is hydrogen, C 1-6 -alkyl, C 1-6 -haloalkyl, --NH 2, --NHR 21 ; R 2 is hydroxyl, --OR 22, three- to seven-membered saturated cycloaliphatic amino optionally interrupted by one or more nitrogen, oxygen or sulfur atoms, --NHR 23, --N(R 24) 2, --NH 2 ; R 4 is hydrogen, C 1-6 -alkyl, or --C( O)R 25 ; R 7 is --CO--, --SO 2 --; R 8 is --CO--, single bond; R 12 is --R 11 --R 5 ; R 11 is --N(R 5)--, --NH--, --O--, --N(R 26)--, --N(C( O)R 27)--, --N(C( O)NH 2)--, --N(C( O)NHR 28)--; R 13 is hydrogen, C 1-6 -alkyl, C 1-6 -haloalkyl, --NHC( O)(CH 2) m C 6 H 5, --NHC( O)R 29, --NHC( O)CH(C 6 H 5) 2, --NH 2, --NHR 30, --(CH 2) n C 6 H 5 ; Z is C, CH, N; A is CH, N; R 5 is hydrogen, --CH 2 C 6 H 4 COOH, --CH 2 C 6 H 4 COOR 31, --CH 2 C 6 H 4 OH, --CH 2 C 6 H 4 OR 32, --CH 2 C 6 H 4 NH 2, --CH 2 C 6 H 4 N(R 33) 2, --CH 2 C 6 H 4 -azole, --CH 2 C 6 H 4 NHR 34, --CH 2 C 6 H 4 C 6 H 4 R 14 ; R 14 is azole, --COOH; R 21 to R 34 are independently C 1-6 -alkyl or C 1-6 -haloalkyl; m is 0 to 6; n is 0 to 6; t is 0 or 1, with the proviso that when Z is N, R 5 is hydrogen, --CH 2 C 6 H 4 COOH, --CH 2 C 6 H 4 COOR 31, --CH 2 C 6 H 4 OH, --CH 2 C 6 H 4 OR 32, --CH 2 C 6 H 4 NH 2, --CH 2 C 6 H 4 N(R 33) 2, --CH 2 C 6 H 4 -azole, or --CH 2 C 6 H 4 NHR 34, or a salt thereof, and a pharmaceutical composition comprising said benzene derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

Esters of 3-nitrocumic acid.

-